Rimycin™
Active ingredients: Rifampicin
Consumer medicine information
Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
INDICATIONS AS AT 5 DECEMBER 2001 : Tuberculosis. In the initial treatment and in retreatment of patients with tuberculosis, rifampicin must be used in conjunction with at least one other antituberculosis drug. Leprosy - In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the non-infectious state which may be expected to occur in three to four months of treatment. - As an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other anti-leprosy drugs. - As an alternative drug in all those patients having true drug allergy to the more commonly used anti-leprosy drugs.,Meningococcal Disease Prophylaxis of meningococcal disease in close contacts of known cases and in carriers (rifampicin is not indicated for the treatment of meningococcal infections).,Haemophilus Influenzae Prophylaxis of household contacts of patients with Haemophilus influenzae type B.,Buruli Ulcer For the treatment of Mycobacterium ulcerans infections (Buruli ulcer). Rifampicin must be used in combination with another anti-Mycobacterium ulcerans antibiotic.INDICATIONS AS AT 5 DECEMBER 2001 : Tuberculosis. In the initial treatment and in retreatment of patients with tuberculosis, rifampicin must be used in conjunction with at least one other antituberculosis drug. Leprosy. (a) In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the non-infectious state which may be expected to occur in three to four months of treatment. (b) As an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other anti-leprosy drugs. (c) As an alternative drug in all those patients having true drug allergy to the more commonly used anti-leprosy drugs. Prophylaxis of meningococcal disease in close contacts of known cases and in carriers (rifampicin is not indicated for the treatment of meningococcal infections). Prophylaxis of household contacts of patients with Haemophilus influenzae type B.
Source: ARTG
Storage conditions
- Shelf lifetime is 24 Months
- Store below 25 degrees Celsius
Source: ARTG
How to use this medicine
Non-composite pack
This medicine contains one component only.
Component
- Capsule, hard
- Oral
- Size 3 hard gelatin capsule, maroon body with black cap.
Source: ARTG
Images

Images © Medicines Information Pty Ltd.
Do I need a prescription?
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.
- 10
- 100
Source: ARTG
Is this medicine subsidised?
This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under PBS item codes 12200D (Opens in new tab) and 1981G (Opens in new tab). Ask your pharmacist or doctor about your eligibility
Source: PBS
Pregnant or planning a pregnancy?
For the active ingredient: Rifampicin
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Source: AHT
Reporting side effects
If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).
You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)
Source: ARTG
Data sources
- Australian Health Thesaurus (AHT) (Opens in new tab) – Last updated on 3 August 2026
- Australian Medicines Terminology (AMT) (Opens in new tab) – Last updated on 3 August 2026
- Australian Register of Therapeutic Goods (ARTG) (Opens in new tab) – Last updated on 3 August 2026
- Pharmaceutical Benefits Scheme (PBS) (Opens in new tab) – Last updated on 3 August 2026
- Medicines Information Pty Ltd (Opens in new tab) – Last updated on 4 March 2026
Disclaimer
Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).
Symptom Checker
Worried about your health?
Select a symptom, answer some questions, get advice